464 related articles for article (PubMed ID: 37765073)
1. Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives.
ElHady AK; El-Gamil DS; Abdel-Halim M; Abadi AH
Pharmaceuticals (Basel); 2023 Sep; 16(9):. PubMed ID: 37765073
[TBL] [Abstract][Full Text] [Related]
2. Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
Zuccarello E; Acquarone E; Calcagno E; Argyrousi EK; Deng SX; Landry DW; Arancio O; Fiorito J
Biochem Pharmacol; 2020 Jun; 176():113818. PubMed ID: 31978378
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
Ahmed WS; Geethakumari AM; Biswas KH
Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
[TBL] [Abstract][Full Text] [Related]
4. Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders.
Samidurai A; Xi L; Das A; Kukreja RC
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():585-615. PubMed ID: 36206989
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Barnes H; Brown Z; Burns A; Williams T
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular effects of phosphodiesterase type 5 inhibitors.
Vlachopoulos C; Ioakeimidis N; Rokkas K; Stefanadis C
J Sex Med; 2009 Mar; 6(3):658-74. PubMed ID: 19138362
[TBL] [Abstract][Full Text] [Related]
7. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
[TBL] [Abstract][Full Text] [Related]
8. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery.
Andersson KE
Br J Pharmacol; 2018 Jul; 175(13):2554-2565. PubMed ID: 29667180
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
Corbin JD; Francis SH; Webb DJ
Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
[TBL] [Abstract][Full Text] [Related]
10. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
11. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
12. New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is).
Ribaudo G; Pagano MA; Bova S; Zagotto G
Curr Med Chem; 2016; 23(12):1239-49. PubMed ID: 27121186
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application.
Hatzimouratidis K; Burnett AL; Hatzichristou D; McCullough AR; Montorsi F; Mulhall JP
Eur Urol; 2009 Feb; 55(2):334-47. PubMed ID: 18986755
[TBL] [Abstract][Full Text] [Related]
14. The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels.
Zhu B; Strada SJ
Curr Top Med Chem; 2007; 7(4):437-54. PubMed ID: 17305584
[TBL] [Abstract][Full Text] [Related]
15. [Novel indications for phosphodiesterase type 5 inhibitors].
Rosenkranz S; Caglayan E; Erdmann E
Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
[TBL] [Abstract][Full Text] [Related]
16. PDE5 inhibitors beyond erectile dysfunction.
Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
[TBL] [Abstract][Full Text] [Related]
17. Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors.
Abdel-Halim M; Tinsley H; Keeton AB; Weam M; Atta NH; Hammam MA; Hefnawy A; Hartmann RW; Engel M; Piazza GA; Abadi AH
Bioorg Chem; 2020 Nov; 104():104322. PubMed ID: 33142429
[TBL] [Abstract][Full Text] [Related]
18. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
[TBL] [Abstract][Full Text] [Related]
19. PDE5 inhibitors in non-urological conditions.
Vlachopoulos C; Terentes-Printzios D; Ioakeimidis N; Rokkas K; Stefanadis C
Curr Pharm Des; 2009; 15(30):3521-39. PubMed ID: 19860698
[TBL] [Abstract][Full Text] [Related]
20. PDE5 inhibitors and their applications.
Giovannoni MP; Vergelli C; Graziano A; Dal Piaz V
Curr Med Chem; 2010; 17(24):2564-87. PubMed ID: 20491634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
